Fmr LLC Buys 154,061 Shares of DaVita Inc. (NYSE:DVA)

FMR LLC increased its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 659.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 177,406 shares of the company's stock after acquiring an additional 154,061 shares during the quarter. FMR LLC owned about 0.22% of DaVita worth $29,082,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of DVA. Harvard Management Co. Inc. bought a new position in DaVita during the 2nd quarter worth approximately $55,115,000. Point72 Asset Management L.P. bought a new position in DaVita in the second quarter valued at approximately $9,615,000. KBC Group NV lifted its stake in DaVita by 27.3% in the third quarter. KBC Group NV now owns 313,519 shares of the company's stock valued at $51,395,000 after buying an additional 67,250 shares in the last quarter. International Assets Investment Management LLC bought a new position in DaVita in the third quarter valued at approximately $10,346,000. Finally, Hennessy Advisors Inc. bought a new position in DaVita in the second quarter valued at approximately $8,439,000. Institutional investors own 90.12% of the company's stock.

DaVita Stock Down 2.7 %

Shares of NYSE DVA traded down $4.29 during midday trading on Tuesday, reaching $153.77. The company's stock had a trading volume of 788,788 shares, compared to its average volume of 813,407. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. DaVita Inc. has a fifty-two week low of $103.40 and a fifty-two week high of $169.51. The stock has a market capitalization of $12.61 billion, a price-to-earnings ratio of 17.05, a PEG ratio of 0.90 and a beta of 0.90. The stock has a 50 day simple moving average of $158.46 and a 200-day simple moving average of $150.52.

DaVita (NYSE:DVA - Get Free Report) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion during the quarter, compared to analyst estimates of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita's revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter last year, the business earned $2.85 earnings per share. Equities research analysts predict that DaVita Inc. will post 9.71 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Javier Rodriguez sold 9,881 shares of the business's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $162.85, for a total transaction of $1,609,120.85. Following the transaction, the chief executive officer now directly owns 887,835 shares in the company, valued at approximately $144,583,929.75. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 2.00% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Truist Financial lifted their price target on shares of DaVita from $165.00 to $175.00 and gave the company a "hold" rating in a research note on Monday, October 7th. Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.